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Abstract
Rhodococcus equi causes fatal pyogranulomatous pneumonia in foals and immunocompromised animals and humans.
Despite its importance, there is currently no effective vaccine against the disease. The actinobacteria R. equi and the human
pathogen Mycobacterium tuberculosis are related, and both cause pulmonary diseases. Recently, we have shown that
essential steps in the cholesterol catabolic pathway are involved in the pathogenicity of M. tuberculosis. Bioinformatic
analysis revealed the presence of a similar cholesterol catabolic gene cluster in R. equi. Orthologs of predicted M. tuberculosis
virulence genes located within this cluster, i.e. ipdA (rv3551), ipdB (rv3552), fadA6 and fadE30, were identified in R. equi RE1
and inactivated. The ipdA and ipdB genes of R. equi RE1 appear to constitute the a-subunit and b-subunit, respectively, of a
heterodimeric coenzyme A transferase. Mutant strains RE1DipdAB and RE1DfadE30, but not RE1DfadA6, were impaired in
growth on the steroid catabolic pathway intermediates 4-androstene-3,17-dione (AD) and 3aa-H-4a(39-propionic acid)-5a-
hydroxy-7ab-methylhexahydro-1-indanone (5a-hydroxy-methylhexahydro-1-indanone propionate; 5OH-HIP). Interestingly,
RE1DipdAB and RE1DfadE30, but not RE1DfadA6, also displayed an attenuated phenotype in a macrophage infection assay.
Gene products important for growth on 5OH-HIP, as part of the steroid catabolic pathway, thus appear to act as factors
involved in the pathogenicity of R. equi. Challenge experiments showed that RE1DipdAB could be safely administered
intratracheally to 2 to 5 week-old foals and oral immunization of foals even elicited a substantial protective immunity
against a virulent R. equi strain. Our data show that genes involved in steroid catabolism are promising targets for the
development of a live-attenuated vaccine against R. equi infections.
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Introduction
Rhodococcus equi is a nocardioform Gram-positive bacterium and
a facultative intracellular pathogen that causes fatal pyogranulo-
matous bronchopneumonia in young foals aged up to five months.
R. equi is also an emerging opportunistic pathogen of immuno-
compromised humans, particularly HIV infected patients [1–3].
Like Mycobacterium tuberculosis, the causative agent of tuberculosis
(TB) in man, R. equi is able to infect, survive and multiply inside the
host cells mainly in alveolar macrophages [4–7]. R. equi and M.
tuberculosis are both members of the class of Actinomycetales and share
physical, biochemical and cell biological characteristics [2].
Antibiotic treatment of R. equi infections is not consistently
successful and is costly due to the necessity of treatment for a
prolonged period of time [8]. More importantly, there is currently
no safe and effective vaccine against R. equi infections.
Virulence of R. equi is dependent on the presence of a plasmid
(approx. 85–95 kb) which is essential for R. equi to survive and
grow in macrophages [9–13]. This virulence plasmid carries a
pathogenicity island, encoding a number of related virulence
associated proteins (Vaps) that includes the immunodominant
surface expressed protein VapA [9,10,14]. Following infection
with R. equi, the presence of the VapA-expressing virulence-
associated plasmid is believed to promote necrotic damage to the
host, which is strongly pro-inflammatory [15,16]. VapA is not
required for host cell necrosis, but has been implicated in early
phagosome development [17]. Consistent with this role, muta-
tional analysis showed that vapA, unlike vapG, is indispensable for
multiplication of R. equi in macrophages and its persistence in mice
[12,18]. Indeed, VapA has been most widely investigated in
vaccine studies for the prevention of R. equi infections. Oral
vaccination of mice with an attenuated Salmonella enterica
Typhimurium vaccine strain expressing VapA protein, for
example, has been shown to confer protection against virulent
R. equi [19,20]. DNA vaccines encoding vapA have also been shown
to stimulate cell-mediated immunity [21,22].
Besides the vap genes, only a limited number of other virulence
genes have been identified in R. equi to date. Random transposon
mutagenesis using Himar1 transposition in R. equi identified a
metabolic gene essential for riboflavin biosynthesis. The riboflavin
auxotrophic mutant was shown to be fully attenuated in
immunocompromised mice and could be safely administered to
young foals [23,24]. Immunization of young foals with the
riboflavin auxotrophic mutant, however, did not afford protection
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against a virulent R. equi challenge [24]. choE, encoding the
extracellular cholesterol oxidase in R. equi, is believed to be
involved in macrophage destruction [25], but is not essential for
virulence [26,27]. Isocitrate lyase, a key enzyme of the glyoxylate
bypass encoded by aceA, was shown to be important for virulence
of R. equi. An aceA mutant was unable to proliferate in
macrophages, was attenuated in mice and, when administrated
to 3-week-old foals, did not induce pneumonic disease [28].
Crucially, a choE aceA double mutant in some cases was still able to
induce severe pneumonia in 1-week-old foals, indicating that the
mutant was not fully safe [27]. Attenuated mutants of R. equi were
also obtained by targeted mutagenesis of htrA, narG, or pepD [29].
pepD in M. tuberculosis H37Rv is controlled by the two-component
regulatory system MprA-MprB [30]. Consistent with this, the
sensor kinase MprB of R. equi 103 was recently found to be
required for intracellular survival [31]. So far, however, none of
the strategies or identified virulence factors has resulted in the
development of a safe vaccine capable of providing protective
immunity against R. equi infection in young foals.
In addition to its pathogenic life-style, R. equi also thrives as a
soil-dwelling microorganism capable of rapid growth in soil and
manure using steroids, such as cholesterol, as sole carbon and
energy sources [32–34]. Microbial steroid degradation of choles-
terol proceeds via the formation of 4-androstene-3,17-dione (AD),
methylhexahydroindane-1,5-dione propionate (HIP; 3aa-H-4a(39-
propionic acid)-7ab-methylhexahydro-1,5-indanedione) and 5-
hydroxy-methylhexahydro-1-indanone propionate (5OH-HIP) as
pathway intermediates (Fig. 1) [35–36]. The cholesterol catabolic
pathway has been implicated in the pathogenicity of M. tuberculosis
H37Rv [36–39]. Inactivation of the Mce4 cholesterol transporter
in R. equi RE1, however, did not reveal an essential role of
cholesterol catabolism in R. equi macrophage survival [34,40].
Transposon mutagenesis had previously defined a subset of genes
required for the survival of M. tuberculosis in murine macrophages.
Amongst several others, rv3551 and rv3552 were predicted to be
essential for the survival of M. tuberculosis H37Rv in vitro in
macrophages [41]. Interestingly, rv3551 and rv3552 are part of the
cholesterol catabolic gene cluster ([36]; Fig. S1). The close
phylogenetic relationship between M. tuberculosis and R. equi
prompted us to hypothesize that the predicted critically important
genes of the cholesterol catabolic pathway in M. tuberculosis
H37RV also are important for the pathogenicity of R. equi RE1. In
this study, we identified the orthologs of rv3551 and rv3552,
designated ipdA and ipdB, respectively, within the cholesterol
catabolic gene cluster of R. equi 103S. The DipdAB mutant of R.
equi RE1 was impaired in growth on the steroid catabolic pathway
intermediates AD and 5OH-HIP. We also observed that
RE1DipdAB was attenuated in vitro in macrophages. RE1DipdAB
could be safely administered to 2–5 week-old foals intratracheally
and oral immunization provided a substantial protection against R.
equi infection. The data suggests that genes important for
methylhexahydroindanone propionate (HIP, 5OH-HIP) degrada-
Author Summary
Rhodococcus equi causes fatal pyogranulomatous bron-
chopneumonia in young foals and is an emerging
opportunistic pathogen of immunocompromised humans.
Despite its importance, there is currently no safe and
effective vaccine against R. equi infections. Like Mycobac-
terium tuberculosis, the causative agent of human tuber-
culosis, R. equi is able to infect, survive and multiply inside
alveolar macrophages. Recently we have shown that
essential steps in the cholesterol catabolic pathway
(encoded by the rv3551, rv3552, fadE30 genes) are involved
in the pathogenicity of M. tuberculosis. We hypothesized
that the orthologous genes in the cholesterol catabolic
gene cluster of R. equi also are essential for its virulence
mechanism. Analysis of the respective R. equi strain RE1
mutants revealed that they were impaired in growth on
intermediates of the steroid catabolic pathway and had
attenuated phenotypes in a macrophage infection assay.
Mutant RE1DipdAB, carrying a deletion of the orthologs of
rv3551 and rv3552, could be safely administered to 2–5
week-old foals intratracheally and oral immunization
provided a substantial protection against infection by a
virulent R. equi strain. Our data show that genes important
for methylhexahydroindanone propionate degradation,
part of the steroid catabolic pathway, are promising
targets for the development of a live-attenuated vaccine
against R. equi infections.
Figure 1. Proposed pathway of 4-androstene-3,17-dione (AD) degradation via b-oxidation of methylhexahydroindanone
propionate intermediates 3aa-H-4a(39-propionic acid)-7ab-methylhexahydro-1,5-indanedione (HIP) and 3aa-H-4a(39-propionic
acid)-5a-hydroxy-7ab-methylhexahydro-1-indanone (5OH-HIP) by Rhodococcus equi. Adapted from [35,46–47]. Numbers represent the
following proposed enzymatic steps of b-oxidation of HIP: 1) ATP dependent HIP-CoA transferase, 2) HIP-CoA 5-reductase, 3) acyl-CoA
dehydrogenase, 4) 2-enoyl-CoA hydratase, 5) 3-hydroxyacyl-coA dehydrogenase, 6) 3-ketoacyl-CoA thiolase. Dashed lines indicate multiple steps.
doi:10.1371/journal.ppat.1002181.g001
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tion, as part of the steroid catabolic pathway, are promising targets
for the development of a live-attenuated vaccine against R. equi
infections.
Results
The R. equi 103S genome encodes two sets of genes
orthologous to rv3551 and rv3552 of M. tuberculosis
H37Rv
Bioinformatic analysis of the sequenced genome of R. equi 103S
[42] revealed the presence of a cholesterol catabolic pathway (Fig.
S1). Within the cholesterol catabolic gene cluster, two genes, i.e.
ipdA (REQ_07170) and ipdB (REQ_07160), encode proteins that are
highly similar to Rv3551 (69% identity) and Rv3552 (67%
identity) of M. tuberculosis H37Rv, respectively. The similarities of
IpdA and IpdB are comparable to those observed between other
homologous proteins of the cholesterol catabolic gene clusters of R.
equi 103S and M. tuberculosis H37Rv (Table S1). The operonic
structure of rv3551 and rv3552 in strain H37Rv was conserved in
R. equi 103S (Fig. S1). Unlike H37Rv, the genome of R. equi 103S
encoded a second set of paralogous proteins, designated IpdA2
and IpdB2, respectively, with highest protein sequence similarities
to IpdA (55% identity) and IpdB (51% identity), respectively. This
second set of genes, designated ipdA2 (REQ_00850) and ipdB2
(REQ_00860), was located outside of the cholesterol catabolic gene
cluster and, unlike the ipdAB operon, was not clustered with an
echA20 paralog.
IpdA carries the PF01144 signature motif of heterodimeric
coenzyme A transferases (http://pfam.sanger.ac.uk; [43]) as well as
the COG1788 signature (http://www.ncbi.nlm.nih.gov/Structure/
cdd/cdd.shtml) of AtoD, the a subunit of acetoacetyl-CoA
transferase of E. coli. Moreover, IpdB contained the COG2057
signature motif of AtoA, the b subunit of acetoacetyl-CoA
transferase of E. coli. Highest overall amino acid sequence similarity
of IpdA and IpdB with characterized proteins in databases was
observed with ORF1 (41% identity) and ORF2 (36% identity) of
Comamonas testosteroni TA441, representing the putative a and b
subunits of a CoA-transferase, respectively, involved in testosterone
catabolism [44]. Mutational analysis in C. testosteroni TA441
suggested that ORF1 is probably involved in the steroid degradation
pathway at a step after ring cleavage into HIP and 2-hydroxyhexa-
2,4-dienoic acid (Fig. 1; [44]). Since tesE, tesF and tesG are thought to
encode the enzymes necessary to degrade 2-hydroxyhexa-2,
4-dienoic acid [45], ORF1 is likely to play a role in HIP degradation.
Thus, we hypothesized that IpdA and IpdB of R. equi most likely
constitute the a-subunit and b-subunit, respectively, of a heter-
odimeric coenzyme A transferase involved in steroid catabo-
lism, more specifically in methylhexahydroindanone propionate
degradation.
R. equi mutant strains RE1DipdAB and
RE1DipdABDipdA2B2 are impaired in steroid catabolism
To substantiate the predicted roles of ipdAB and ipdA2B2 in
steroid catabolism, we constructed R. equi unmarked gene deletion
mutant strains RE1DipdAB, RE1DipdA2B2 and RE1DipdABDip-
dA2B2 using the two-step homologous recombination strategy with
5-fluorocytosine counter-selection [34]. Deletion of the target
genes ipdAB and/or ipdA2B2 was confirmed by PCR for all three
mutant strains (Table S2, data not shown). PCR amplicons of the
expected sizes were obtained for RE1DipdAB mutant (296 bp),
RE1DipdA2B2 (123 bp) and RE1DipdABDipdA2B2 (296 bp and
123 bp, respectively). Analyses of the upstream and downstream
regions of the deleted loci by PCR further confirmed genuine gene
deletions and the absence of aberrant genomic rearrangements for
all three mutants (Table S2). The presence of vapA as a marker for
the virulence plasmid was also confirmed by PCR in each of the
mutants (Table S2).
The growth of all three mutant strains on standard acetate
mineral media was comparable to wild type strain RE1 (data not
shown). Wild type strain RE1 also showed good growth on the
steroid substrate AD as a sole carbon and energy source. By
contrast, mutant strain RE1DipdAB was severely impaired in
growth on AD (Fig. 2A). RE1DipdAB displayed an extensive lag-
phase in growth of more than 24 h compared to wild type strain
RE1. This growth phenotype of RE1DipdAB was fully comple-
mented following the introduction of a 4,453 bp DNA fragment
carrying wild type ipdAB under its native promoter (Table S2),
restoring growth on AD to levels comparable to the wild type
(Fig. 2C). Since RE1DipdABDipdA2B2 showed complete blockage
of growth on AD, the observed growth of RE1DipdAB following
the lag-phase appeared to be due to the presence of the paralogous
gene set ipdA2B2 partly complementing the ipdAB mutation
(Fig. 2A). RE1DipdA2B2 on the other hand was not impaired in
growth on AD and grew comparably to wild type strain, indicating
that ipdAB, located within the cholesterol gene cluster, is the
dominant ipd gene set involved in steroid catabolism.
Next, we investigated whether ipdAB and ipdA2B2 were involved
in the catabolism of one of the predicted methylhexahydroinda-
none propionate intermediates of steroid degradation, i.e. 5OH-
HIP (Fig. 2B). The growth phenotype of the mutants in the
presence of 5OH-HIP as the sole carbon and energy source was
comparable to those observed for AD: an extensive lag-phase in
bacterial growth on 5OH-HIP was observed for strain RE1-
DipdAB, whereas hardly any impairment in growth was observed
for RE1DipdA2B2. Finally, mutant strain RE1DipdABipdA2B2
displayed no growth on 5OH-HIP at all. To further substantiate
the predicted involvement of ipdAB and ipdA2B2 in methylhex-
ahydroindanone propionate degradation, we performed whole cell
biotransformation experiments with cell cultures grown in mineral
acetate medium and incubated with AD. Wild type strain RE1
fully degraded AD (0.5 g/l) within 24 hours without the
accumulation of HIP or 5OH-HIP (data not shown). Accumula-
tion of HIP from AD, however, was observed for mutant strain
RE1DipdABDipdA2B2 (Fig. 3). A temporary accumulation of HIP,
24 hours after the addition of AD, was also detected in
biotransformations with strain RE1DipdAB (data not shown).
HIP formed by RE1DipdAB was, however, fully degraded after
120 hours of incubation (Fig. 3), consistent with its growth
phenotypes on AD and 5OH-HIP. Thus, the ipdAB genes,
encoding a heterodimeric CoA transferase in R. equi RE1, are
important for growth on steroids and fulfil a role in the lower part
of the steroid catabolic pathway, more specifically in methylhex-
ahydroindanone propionate degradation.
Inactivation of genes involved in
methylhexahydroindanone propionate catabolism
attenuates R. equi RE1 infection of macrophages
To investigate whether the ipdAB genes of R. equi RE1 are
important for survival in macrophages, analogously to the
predicted important role of rv3551 and rv3552 in M. tuberculosis
H37Rv [41], in vitro macrophage infection assays were performed.
Macrophage infection experiments showed that strain RE1DipdAB
and strain RE1DipdABDipdA2B2 were significantly attenuated,
comparable to the avirulent R. equi strain 103- lacking the
virulence plasmid [10] (Fig. 4A). Control experiments with virulent
wild type strain R. equi RE1 showed that the parent strain was able
to infect macrophages (Fig. 4A). Inactivation of ipdAB was
sufficient to significantly impair macrophage infection by R. equi
Role Steroid Catabolism in R. equi Pathogenicity
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RE1 and additional deletion of ipdA2B2 had no further attenuating
effect (Fig. 4A). Consistent with this result, inactivation of ipdA2B2
alone did not result in attenuation, indicating that ipdAB is the
dominant gene set involved in R. equi RE1 pathogenicity (Fig. 4B).
The attenuation of RE1DipdAB was fully complemented by the
introduction of wild type ipdAB (Fig. 4C), excluding the possibility
that the attenuation was due to a mutation unrelated to ipdAB.
To investigate whether other genes with a role in steroid
catabolism are important for macrophage infection by R. equi RE1
we constructed additional gene deletion mutants. We chose to
inactivate two other genes that were located in close proximity to
ipdAB within the cholesterol catabolic gene cluster and had been
predicted as important for survival of M. tuberculosis H37Rv in
macrophages, i.e. fadE30 (REQ_07030) and fadA6 (REQ_07060)
(Fig. S1; [36,41]). Mutant strains RE1DfadA6 and RE1DfadE30
were subsequently tested for growth on AD and 5OH-HIP as sole
carbon and energy sources. RE1DfadE30 was severely impaired in
growth on AD and growth on 5OH-HIP was fully blocked (Fig. 2).
The growth phenotype of RE1DfadE30 was fully complemented
following the introduction of wild type fadE30 under its native
promoter (Table S2), restoring growth on AD and 5OH-HIP to
levels comparable to wild type (Fig. 2C and 2D). Consistent with
the growth phenotypes of RE1DfadE30, cell cultures of mutant
strain RE1DfadE30 accumulated 5OH-HIP during biotransfor-
mation of AD (Fig. 3). Thus, fadE30 plays an essential role in
steroid catabolism at the level of methylhexahydroindanone
propionate degradation. By contrast, RE1DfadA6 was not affected
and able to rapidly grow on both 5OH-HIP and AD, comparable
to parent strain RE1 (Fig. 2). This suggests that fadA6 of R. equi
RE1 is not essential for AD and 5OH-HIP catabolism. However,
further analysis revealed that the genome of R. equi 103S codes for
an apparent paralog of FadA6 (REQ_21310) with 70% protein
sequence identity. The possibility that fadA6 of RE1 is involved in
steroid catabolism, but is not essential due to the presence of the
gene paralog, therefore cannot be excluded at this point.
Macrophage infection assays revealed that strain RE1DfadE30
was significantly attenuated, comparable to that of the attenuated
mutant strains RE1DipdAB and RE1DipdABDipdA2B2, and the
avirulent control strain R. equi 103- (Fig. 4A). The attenuation of
RE1DfadE30 could be fully reversed by the introduction of wild
type fadE30, indicating that attenuation was solely due to fadE30
gene inactivation (Fig. 4C). Interestingly, RE1DfadA6 was not
attenuated and showed survival curves similar to parent strain
RE1 (Fig. 4B), consistent with our hypothesis that R. equi RE1
mutant strains impaired in growth on methylhexahydroindanone
propionate are attenuated.
Figure 2. Growth curves of wild type, mutant and complemented mutant strains of R. equi RE1 in mineral medium supplemented
with 4-androstene-3,17-dione (AD) or 3aa-H-4a(39-propionic acid)-5a-hydroxy-7ab-methylhexahydro-1-indanone (5OH-HIP) as a
sole carbon and energy source. Panels A and B show growth curves of wild type strain (diamonds) and mutants strains RE1DipdAB (squares),
RE1DipdA2B2 (triangles), RE1DipdABDipdA2B2 (crosses), RE1DfadE30 (asterisks) and RE1DfadA6 (circles) in MM+AD and MM+5OH-HIP, respectively.
Panels C and D show growth curves of complemented strains of RE1DipdAB (diamonds) and RE1DfadE30 (squares) in MM+AD and MM+5OH-HIP,
respectively. Curves represent averages of two independent experiments. Error bars represent standard deviations. Media with AD are turbid;
therefore culture protein content was measured instead of optical density.
doi:10.1371/journal.ppat.1002181.g002
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Intratracheal challenge of foals revealed in vivo
attenuation of mutant strain RE1DipdAB
The attenuated phenotype of RE1DipdAB in our in vitro
macrophage infection model suggested that strain RE1DipdAB
also might be attenuated in foals. This prompted us to perform
an in vivo intratracheal challenge experiment in young foals. In
vivo attenuation of the RE1DipdAB mutant was tested in foals
aged 3–5 weeks. The foals were equally divided into two groups
of three (n = 3). One group was challenged intratracheally with
mutant strain RE1DipdAB (7.16106 CFU) and the other group
with wild type strain RE1 (4.36106 CFU) as a control. During a
period of 3 weeks post-challenge the foals were clinically scored.
None of the foals challenged with RE1DipdAB developed signs of
respiratory disease and no increase in rectal temperatures of
these foals was observed (Fig. 5). By contrast, two out of three
foals in the wild type infected group developed severe clinical
signs of respiratory disease, coinciding with increased rectal
temperatures from 14 days post-challenge onwards. One wild
type infected foal showed only mild clinical signs post-challenge.
Mean daily weight gains post-challenge were substantially higher
for foals challenged with RE1DipdAB (27.9 6 5.2%) compared to
those challenged with RE1 (18.9 6 1.3%). Serum blood analyses
revealed that the RE1DipdAB mutant strain was able to elicit a
substantial serum antibody titer against R. equi, although the
titers were lower than those observed in foals challenged with
strain RE1 (Fig. 6). At 3 weeks post-challenge all foals were
euthanized and subjected to a complete post-mortem examina-
tion. Foals challenged with wild type strain RE1 had developed
typical pyogranulomatous pneumonia from which wild type R.
equi successfully was re-isolated (Table 1). The lungs of the foals
challenged with the mutant strain, on the other hand, did not
reveal pneumonic areas and R. equi could not be isolated
(Table 1). Consistent with these observations, the mean
percentage lung-to-body weight of foals challenged with wild
type RE1 (2.0 6 0.6%) was twice as high as those challenged
with mutant strain RE1DipdAB (1.0 6 0.06%).
Oral immunization of foals with RE1DipdAB provides
substantial protection against an intratracheal challenge
The challenge experiments indicated that RE1DipdAB was
attenuated in young foals and able to induce an immunological
response. To test RE1DipdAB as a live-attenuated vaccine-
candidate in providing protective immunity against an intratra-
cheal challenge with virulent R. equi, we performed an
immunization experiment. Eight 2 to 4-week-old foals were used
for this experiment and divided into two groups of four foals
(n = 4). At T = 0 and at T = 14 days (booster) one group was
vaccinated orally (1 ml) with strain RE1DipdAB (56107 CFU/
animal) and the other group was left as unvaccinated control.
After vaccination, all foals remained healthy and no vaccine-
related abnormalities were observed. Rectal temperatures
remained normal in all foals (data not shown). Strain RE1DipdAB
could not be re-isolated from rectal swabs, indicating that the
mutant strain did not massively colonize the alimentary tract.
Serum blood analyses revealed substantial serum antibody titers
against R. equi following vaccination (Fig. 7). These post-
vaccination results were consistent with the results obtained from
the challenge experiment and confirmed that mutant strain
RE1DipdAB was attenuated in vivo and can be safely administered
to young foals.
All foals were subsequently challenged intratracheally with
virulent strain R. equi 85F (56106 CFU), displaying strong
cytotoxicity [16], two weeks after the booster vaccination
(T = 28 days). During a period of 3 weeks post-challenge the
foals were clinically scored. Then foals were euthanized and
subjected to a complete post-mortem examination with special
attention to the lungs and respiratory lymph nodes as well as the
gut and associated lymph nodes. All four foals in the control
group showed increasing signs of respiratory disease from day 7
to 10 post-challenge onwards (Fig. 8; T = 35–38 days). The
control foals were euthanized 14 days post challenge (T = 42
days) for humane reasons. Post-mortem macroscopic and
microscopic analysis confirmed pyogranulomatous pneumonia
in the control foals with severe pulmonary consolidations from
which wild type R. equi was re-isolated as identified by PCR
(Tables 2 and 3; Fig. 9). Wild type R. equi was also isolated in high
numbers from swollen mediastinal lymph nodes and in one foal
from a caecal lymph node. By contrast, the vaccinated foals had
much milder clinical signs or virtually no clinical signs at all
(Fig. 8). Two vaccinated foals remained completely healthy and
post-mortem macroscopic analysis did not reveal any signs of
pyogranulomatous pneumonia. Two other vaccinates had locally
developed pyogranulomatous pneumonia with pulmonary con-
solidations in the accessory and caudal lobes from which wild
type R. equi was isolated (Tables 2 and 3). Overall, the numbers of
wild type R. equi isolated from the lungs of the vaccinated foals
were substantially lower than those found in the control group.
We conclude that vaccination of young foals with strain
RE1DipdAB is safe and induces a substantial protective immunity
against a severe intratracheal challenge with a virulent R. equi
strain.
Discussion
The current study identified the cholesterol catabolic gene cluster
in R. equi and showed that ipdAB and fadE30 located within this
cluster are important for the pathogenicity of R. equi RE1.
Interestingly, R. equi RE1 mutants that displayed attenuated
phenotypes in an in vitro macrophage infection assay were also
impaired in steroid catabolism, i.e. RE1DipdAB, RE1DipdABDip-
dA2B2 and RE1DfadE30. Conversely, mutants that had AD growth
phenotypes comparable to wild type strain RE1, i.e. RE1DipdA2B2
and RE1DfadA6, were not attenuated. Both fadE30 and ipdAB were
also shown to be important for 5OH-HIP catabolism. Biochemical
and physiological studies previously showed that the degradation of
the propionate moiety of HIP and 5OH-HIP likely occurs via a
cycle of b-oxidation [35,46–47] (Fig. 1). ATP-dependent CoA
activation was suggested to be the first step in the degradation of
HIP in R. equi ATCC14887 [46]. Protein sequence analysis revealed
that IpdA and IpdB represent the a and b-subunit of a
heterodimeric CoA-transferase. The heterodimeric CoA-transferase
encoded by ipdAB thus might be involved in the removal of
the propionate moiety of methylhexahydroindanone propionate
Figure 3. Gas chromatography profiles showing the formation of methylhexahydroindanone propionate intermediates during
whole cell biotransformations of 4-androstene-3,17-dione (AD) by mutant strains of R. equi RE1 at T =120 hours. Methylhexahy-
droindane-1,5-dione propionate (HIP) and 5-hydroxy-methylhexahydro-1-indanone propionate (5OH-HIP) accumulation in cell cultures of
RE1DipdABDipdA2B2 and RE1DfadE30, respectively. No accumulation is observed in cell cultures of RE1DipdAB. Lower panel shows the GC profiles
of HIP (200 mg/L) and 5OH-HIP (50 mg/L) as authentic samples. Abbreviations: 1,4-androstadiene-3,17-dione (ADD), 3-hydroxy-9,10-secoandrost-
1,3,5(10)-triene-9,17-dione (3-HSA), progesterone (50 mg/L) internal standard (I.S.).
doi:10.1371/journal.ppat.1002181.g003
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intermediates (i.e. HIP, 5OH-HIP) by b-oxidation during steroid
degradation (Fig. 1, step 1). Consistent with such a role, HIP
accumulation was observed in biotransformation experiments with
cell cultures of RE1DipdABDipdA2B2 incubated with AD (Fig. 3).
FadE30 belongs to the family of acyl-CoA dehydrogenases and
might catalyze the second step in the b-oxidation cycle that removes
the propionate moiety following CoA activation by IpdAB, i.e. the
dehydrogenation of 5OH-HIP-CoA (Fig. 1, step 3). Accumulation
of 5OH-HIP indeed was observed in biotransformation experi-
ments with cell cultures of RE1DfadE30 incubated with AD (Fig. 3).
Figure 4. Macrophage infection assays of the human monocyte cell line U937 with R. equi strains. Macrophage cell suspensions were
infected with wild type virulent strain R. equi RE1 or mutant strains RE1DipdAB, RE1DipdA2B2, RE1DipdABDipdA2B2, RE1DfadE30 and RE1DfadA6. The
numbers of intracellular bacteria were determined by plate counts in duplicate following macrophage lysis. The data represents the averages for at
least three independent experiments. Error bars represent standard deviations. Panel A shows the results for attenuated mutant strains RE1DipdAB,
RE1DipdABDipdA2B2 and RE1DfadE30. Avirulent strain R. equi 103- was used as a control. Panel B shows the results for non-attenuated mutant strains
RE1DipdA2B2 and RE1DfadA6. Statistically, mutant strains RE1DipdAB (P,0.02), RE1DipdABDipdA2B2 (P,0.01) and RE1DfadE30 (P,0.01) were
significantly attenuated compared to parent strain RE1. Panel C shows the results (duplicates) with complemented mutant strains of RE1DfadE30 and
RE1DipdAB. Wild type RE1, strain 103+, and mutant strains RE1DipdAB and RE1DfadE30 were included as controls.
doi:10.1371/journal.ppat.1002181.g004
Role Steroid Catabolism in R. equi Pathogenicity
PLoS Pathogens | www.plospathogens.org 7 August 2011 | Volume 7 | Issue 8 | e1002181
Interestingly, ipdA and ipdB appear to be part of an operon
encompassing echA20 (Fig. S1), encoding a putative enoyl-coA
hydratase that might catalyse the subsequent step in the b-oxidation
cycle during the degradation of the propionate moiety (Fig. 1, step
4). However, functions of ipdAB, fadE30 and echA20 further down in
the degradation pathway of these compounds cannot be excluded
and need further investigation.
A second set of paralogous genes, designated ipdA2 and ipdB2,
was additionally identified in R. equi RE1 which do not play an
important role in AD or 5OH-HIP catabolism. Still, ipdA2B2 are
involved in growth on AD and 5OH-HIP, since ipdA2B2 are able
to support the growth of mutant strain RE1DipdAB on AD and
5OH-HIP, albeit after an extensive lag-phase (Fig. 2). The data
suggests that the primary role of ipdA2B2 is not in AD or 5OH-
HIP catabolism, but that they are recruited in the DipdAB mutant,
perhaps through a genetic mutation. Protein sequence similarities
between IpdA and IpdA2 and between IpdB and IpdB2 are
relatively low, which suggests that IpdAB and IpdA2B2 are related
proteins, but have different physiological functions. This is further
supported by the genomic location of ipdA2 and ipdB2 in a region
distant from the cholesterol catabolic gene cluster and with no
apparent clustering of steroid genes. Consistently, ipdA2B2 does
not appear to be involved in pathogenesis. Due to the likely
different physiological function of ipdA2B2 in R. equi these genes
may be expressed differently relative to ipdAB, or even not at all,
during R. equi infection.
Figure 5. Intratracheal challenge of 3 to 5-week-old foals. Foals (mean of n=3) were challenged intratracheally with mutant R. equi
RE1DipdAB (7.16106 CFU; squares) or wild type RE1 (4.36106 CFU; diamonds). Panel A shows rectal temperatures. Panel B shows numerical
clinical scores. Error bars represent standard deviation.
doi:10.1371/journal.ppat.1002181.g005
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Overall, our results strongly imply that the pathogenicity of R.
equi correlates with the steroid catabolic pathway, in particular
with methylhexahydroindanone propionate (HIP, 5OH-HIP)
degradation. Several other examples of virulence-associated genes
important for microbial steroid ring degradation have been
reported. The kshA and kshB genes of M. tuberculosis H37Rv, for
example, were shown to be essential for pathogenicity of H37Rv
[39]. These genes encode the two-component iron-sulfur protein
3-ketosteroid 9a-hydroxylase, which is a key-enzymatic step in
microbial steroid ring opening [48]. The steroid ring-cleaving
dioxygenase HsaC, catalyzing the further breakdown of steroids
towards methylhexahydroindanone propionate pathway interme-
diates, also contributes to the pathogenicity of M. tuberculosis
H37Rv [38]. We do not yet understand why genes of the steroid
catabolic pathway are important for the pathogenicity of R. equi.
Considering that many steroids are known to have immuno-
regulatory properties, steroids could play an important role during
R. equi infection. In vivo, b-androstenes, such as 3b-hydroxy-5-
androstene-17-one (DHEA) and 5-androstene-3b,17b-diol, have
been associated with immune-homeostasis during bacterial
infection [49]. Thus, ipdAB, fadE30 and other genes involved in
steroid ring degradation may help R. equi to disrupt the immune-
homeostasis in a yet unknown way, favouring infection of the
macrophage. Intriguingly, attenuated mutant strains RE1DipdAB,
RE1DipdABDipdA2B2 and RE1DfadE30 consistently showed
significantly lower bacterial counts in our macrophage infection
assay at T = 4 h post-infection (Fig. 4A) compared to wild type
strains RE1 and avirulent strain 1032, which suggests that the
attenuated mutants are affected in processes that occur early in the
infection. Whether these processes are involved in immune-
homeostasis or are related to some other process, such as impaired
adherence or uptake of R. equi by the macrophage, remains to be
elucidated.
It is noteworthy to mention that, for reasons unknown, wild type
R. equi strains RE1 and 103+ do not appear to replicate well in the
human macrophage cell line U937 when compared to the
replication of wild type R. equi in murine or equine primary
macrophages.
A subset of genes of the cholesterol gene cluster present in
Mycobacterium smegmatis mc2155, designated the kstR2 regulon, was
recently shown to be controlled by the TetR-type transcriptional
regulator kstR2 [50]. An apparent orthologue of kstR2 of M.
smegmatis mc2155 was also found present in the cholesterol gene
cluster of R. equi 103S, encoding a protein with 56% amino acid
sequence identity and located between fadE30 and fadA6 (Fig. S1).
Interestingly, the fadA6, fadE30 and ipdAB orthologues in M.
smegmatis mc2155 all are part of the kstR2 regulon [50]. Most likely,
the kstR2 regulon of M. smegmatis mc2155 is involved in
methylhexahydroindanone propionate catabolism. The presence
of a putative kstR2 regulon in R. equi 103S raises the intriguing
question whether all genes belonging to this regulon are important
for R. equi pathogenicity.
Several vaccination strategies have been explored to date in an
attempt to prevent infection by the opportunistic horse pathogen
R. equi. So far, these have not resulted in the development of a safe
Figure 6. Serum antibody titer against R. equi of 3 to 5-week-
old foals (n =3) at day of intratracheal challenge (T=0 days)
and 3-weeks post-challenge (T=21 days) with mutant R. equi
RE1DipdAB (7.16106 CFU; grey bars) or wild type RE1
(4.36106 CFU; white bars). Values represent mean 6 standard
deviation (error bars).
doi:10.1371/journal.ppat.1002181.g006
Table 1. Pulmonary consolidation and re-isolation of R. equi of 3 to 5-week-old foals (n = 3) challenged intratracheally with wild




weight (%) Pulmonary consolidation per lobe (%)
a
Isolation of R. equi
from lung (log10 CFU/ml
homogenate) b
Apical left Apical right Caudal left Caudal right Accessory
RE1 1 1.4 5 30 5 30 30 4.2 6 0.57
2 2.6 10 0 60 40 70 6.8 6 0.67
3 1.9 50 70 50 70 90 3.1 6 2.2
Mean 2.0 22 33 38 47 63 4.7 6 1.8
RE1 DipdAB 4 1.0 0 0 0 0 0 0
5 1.1 0 0 0 0 0 0
6 1.0 0 0 0 0 0 0
Mean 1.0 0 0 0 0 0 0
apercentage of pulmonary consolidation was determined by an experienced pathologist.
baverage value calculated from numbers found in apical, lower caudal, upper caudal and accessory lobes.
doi:10.1371/journal.ppat.1002181.t001
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Figure 7. Serum antibody titer against R. equi of foals (n =4) immunized orally (grey bars) at T=0 and T=14 days with attenuated R.
equi strain RE1DipdAB (56107 CFU) and challenged at T=28 days with R. equi strain 85F (56106 CFU). The serum antibody titer of
unvaccinated control foals (n = 4) are shown in white bars. Bars represent mean titers at day of vaccination (T = 0), at day of booster vaccination
(T = 14), at day of intratracheal challenge (T = 28) and 20 days post-challenge (T = 48). Error bars represent standard deviation.
doi:10.1371/journal.ppat.1002181.g007
Figure 8. Oral immunization and subsequent intratracheal challenge of foals. Foals (2 to 4-week-old) vaccinated with RE1DipdAB (squares)
and non-vaccinated controls (diamonds) (mean of n = 4) were challenged intratracheally with virulent strain R. equi 85F (56106 CFU). Panel A shows
rectal temperatures. Panel B shows numerical clinical scores. Statistically, rectal temperatures (P,0.005) and clinical scores (P,0.0001) were
significantly different in vaccinates compared to the non-vaccinated control foals. Error bars represent standard deviation.
doi:10.1371/journal.ppat.1002181.g008
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and effective vaccine against R. equi infection. Indeed, protection
has been observed when wild type virulent R. equi was
administrated orally [51–53]. However, this vaccination approach
cannot be used due to the high risk of provoking disease and
contamination of the environment. Immunization procedures
using avirulent (plasmid-less) or killed R. equi cells, on the other
hand, do not induce a protective immune response [52] and
underline the importance of developing a live-attenuated vaccine
strain. The administration of specific hyperimmune plasma
currently has been the only method providing a positive effect in
Table 2. Lung weights and percentage pulmonary consolidation per lobe of vaccinated and unvaccinated (control) 2 to 4-week-





total weight (%) Pulmonary consolidation per lobe (%)
a
Apical left Apical right Caudal left Caudal right Accessory
Vaccinate 1 8 1.4 0 0 50 5 40
Vaccinate 2 8 1.0 1b 1b 1b 1b 0
Vaccinate 3 7 1.2 3b 0 10 10 70
Vaccinate 4 7 1.1 0 0 0 0 0
Mean vaccinates 1.2 1 0 15 4 28
Control 1 8 2.6 10 60 80 80 90
Control 2 8 2.0 0 50 40 70 70
Control 3 7 3.4 10 60 70 70 90
Control 4 6 2.9 0 10 40 80 100
Mean controls 2.7 5 45 58 75 88
Foals were vaccinated orally at T = 0 and T= 2 weeks with RE1DipdAB (56107 CFU/animal). Foals were challenged intratracheally at T = 4 weeks with the highly virulent
strain R. equi 85F (56106 CFU/animal). Statistically, pulmonary consolidation was significantly different in vaccinates compared to the non-vaccinated control foals
(P,0.01).
apercentage of pulmonary consolidation was determined by an experienced pathologist.
bconsolidated, but not pyogranulomatous.
doi:10.1371/journal.ppat.1002181.t002
Figure 9. Histopathology of lung tissue of vaccinates versus non-vaccinated foals following intratracheal challenge with wild type
R. equi. Lung specimen of a vaccinated foal showing normal airways (bronchi and bronchioli), blood vessels and alveoli at (A) 25x and (B) 200x
magnification. Typical pyogranuloma (5 mm diameter) observed in lung specimens of non-vaccinated control foals at (C) 25x and (D) 200x
magnification. The centre of the pyogranuloma consists of necrotic debris, neutrophils and toxic neutrophils with complete loss of lung architecture.
doi:10.1371/journal.ppat.1002181.g009
Role Steroid Catabolism in R. equi Pathogenicity
PLoS Pathogens | www.plospathogens.org 11 August 2011 | Volume 7 | Issue 8 | e1002181
avoiding foals of an endemic farm to develop R. equi pneumonia
[54–56]. The method, however, is expensive, labour intensive and
not consistently effective [57–59]. Our strategy targeted genes in
the cholesterol catabolic gene cluster of R. equi to develop a live-
attenuated vaccine. Our data revealed that RE1DipdAB is a highly
promising candidate for a live-attenuated vaccine strain providing
substantial protective immunity. Full immunity following oral
immunization with RE1DipdAB was not yet observed in the
vaccination experiment, since two foals showed mild signs of
pneumonic disease following a severe challenge with R. equi 85F
(Tables 2 and 3). However, re-isolation of wild type R. equi was
several log10 fold lower in lungs of immunized foals compared to
those of non-vaccinated controls (Table 3), strongly suggesting that
protection had not yet fully developed. Further optimization of the
vaccination protocol to increase its efficacy, as well as field trials, is
currently on the way to develop the first safe and effective live-
attenuated vaccine against R. equi infection in young foals.
The incidence of R. equi infection in humans has increased
markedly with human immunodeficiency virus (HIV) infection, as
well as with the development of organ transplantations and
chemotherapy for malignancies [1,60–61]. The infection mortality
rate is still high (20–25%), especially for AIDS patients (50–55%),
and disease relapses are common [60,62]. The steroid catabolic
pathway of R. equi therefore may provide interesting novel targets
for drug development to treat R. equi infection in humans, as many
of the catabolic enzymes have no human homolog.
Materials and Methods
Culture media and growth conditions
R. equi RE1 was isolated from a foal with pyogranulomatous
pneumonia in the Netherlands in September 2007 [34]. Strains R.
equi 103+ [14], R. equi 1032 [63] and R. equi 85F [52,64] have
been previously described. R. equi cell cultures were routinely
grown at 30uC (200 rpm) in Luria-Bertani (LB) medium consisting
of Bacto-Tryptone, Yeast Extract and 1% NaCl, or mineral
acetate medium (MM-Ac) containing K2HPO4 (4.65 g/l), NaH2-
PO4?H2O (1.5 g/l), sodium acetate (2 g/l), NH4Cl (3 g/l),
MgSO4?7H2O (1 g/l), thiamine (40 mg/l, filter sterile), and
Vishniac stock solution (1 ml/l). Vishniac stock solution was
prepared as follows (modified from Vishniac and Santer [65]):
EDTA (10 g/l) and ZnSO4.7H2O (4.4 g/l) were dissolved in
distilled water (pH 8.0 using 2 M KOH). Then, CaCl2.2 H2O
(1.47 g/l), MnCl2.7 H2O (1 g/l), FeSO4.7 H2O (1 g/l), (NH4)6
Mo7O24.4 H2O (0.22 g/l), CuSO4.5 H2O (0.315 g/l) and
CoCl2.6 H2O (0.32 g/l) were added in that order maintaining
pH at 6.0 and finally stored at pH 4.0. For growth on 4-
androstene-3,17-dione (AD, 0.5 g/l) or 3aa-H-4a(39-propionic
acid)-5a-hydroxy-7ab-methylhexahydro-1-indanone (5OH-HIP,
1 g/l) as sole carbon and energy source sodium acetate was
omitted from the medium. Stock solutions of 5OH-HIP (100 mg/
ml), prepared by dissolving 100 mg 3aa-H-4a(39-propionic acid)-
5a-hydroxy-7ab-methylhexahydro-1-indanone-d-lactone (HIL) in
1 ml 0.5M NaOH, and AD (50 mg/ml in dimethylsulfoxide
(DMSO)) were used. Cultures (50 ml) were inoculated (1:100)
using pre-cultures grown in MM-Ac. Growth was followed by
regular turbidity measurements (OD600nm). Turbidity measure-
ments of AD grown cultures could not be accurately determined
due to high background of the AD suspension. Protein content of
the culture was therefore used as a measure for biomass formation
and was determined as follows. A sample (0.5 ml) of the culture
was pelleted by centrifugation (5 min 12,000 x g), thoroughly
resuspended in 0.1 ml 1 M NaOH and boiled for 10 min. Then,
0.9 ml distilled water was added and the suspension was vortexed.
An aliquot of 100 ml was mixed with 300 ml of distilled water and
100 ml of protein assay reagent (BioRad). Protein content of the
sample was determined using bovine serum albumin (BSA) as a
standard as described by the manufacturer. For growth on solid
media Bacto-agar (15 g/l; BD) was added. 5-Fluorocytosine stock
solution (10 mg/ml) was prepared in distilled water, dissolved by
heating to 50uC, filter-sterilized and added to autoclaved media.
Cloning, PCR and genomic DNA isolation
Escherichia coli DH5a was used as host for all cloning procedures.
Restriction enzymes were obtained from Fermentas GmbH.
Chromosomal DNA of cell cultures was isolated using the
GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich) according
to the instructions of the manufacturer. PCR was performed in a
reaction mixture (25 ml) consisting of Tris-HCl (10 mM, pH 8), 1x
standard polymerase buffer, dNTPs (0.2 mM), DMSO (2%), PCR
primers (10 ng/ml each) and High-Fidelity DNA polymerase
enzyme (Fermentas) or Pwo DNA polymerase (Roche Applied
Table 3. Quantitative re-isolation of R. equi 85F from lung lobes of vaccinated and unvaccinated (control) 2 to 4-week-old foals
(n = 4).
Foal R. equi 85F (log10 CFU/ml homogenate)
Apical lung lobe Upper caudal lung lobe Lower caudal lung lobe Accessory Lobe Mean Lung
Vaccinate 1 0 0 4.26 5.18 2.36
Vaccinate 2 0 0 0 0 0
Vaccinate 3 0 5.13 0 6.15 2.82
Vaccinate 4 0 0 0 0 0
Mean vaccinates 0.00 1.28 1.07 2.83 1.30
Control 1 8.20 9.19 8.97 8.90 8.82
Control 2 6.75 7.02 7.11 6.96 6.96
Control 3 8.81 8.89 9.08 8.86 8.91
Control 4 5.19 6.13 5.95 6.38 5.91
Mean controls 7.24 7.81 7.78 7.78 7.65
Foals were vaccinated orally at T = 0 and T= 2 weeks with RE1DipdAB (56107 CFU/animal). All foals were challenged intratracheally at T = 4 weeks with virulent wild type
strain R. equi 85F (56106 CFU/animal). Statistically, the bacterial count was significantly different in vaccinates compared to the non-vaccinated control foals (P,0.002).
doi:10.1371/journal.ppat.1002181.t003
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Science). For colony PCR, cell material was mixed with 100 ml of
chloroform and 100 ml of 10 mM Tris-HCl pH 8, vortexed
vigorously and centrifuged (2 min, 14,000 x g). A sample of the
upper aqueous phase (1 ml) was subsequently used as template for
PCR. A standard PCR included a 5 min 95uC DNA melting step,
followed by 30 cycles of 45 sec denaturing at 95uC, 45 sec
annealing at 60uC and 1–3 min elongation at 72uC. The
elongation time used depended on the length of the expected
PCR amplicon, taking 1.5 min/1 kb as a general rule.
Electrotransformation of R. equi strains
Cells of R. equi strains were transformed by electroporation
essentially as described [34]. Briefly, cell cultures were grown in
50 ml LB at 30uC until OD600 reached 0.8–1.0. The cells were
pelleted (20 min at 4,500 x g) and washed twice with 10% ice-cold
glycerol. Pelleted cells were re-suspended in 0.5–1 ml ice-cold
10% glycerol and divided into 200 ml aliquots.
MilliQ-eluted plasmid DNA (5–10 ml; GenElute Plasmid
Miniprep Kit, Sigma-Aldrich) was added to 200 ml cells in
2 mm gapped cuvettes. Electroporation was performed with a
single pulse of 12.5 kV/cm, 1000V and 25 mF. Electroporated
cells were gently mixed with 1 ml LB medium (R. equi) and allowed
to recover for 2 h at 37uC and 200 rpm. Aliquots (200 ml) of the
recovered cells were plated onto selective agar medium. R. equi
transformants were selected on LB agar containing apramycin
(50 mg/ml) and appeared after 2–3 days of incubation at 30uC.
Construction of unmarked gene deletion mutants of
Rhodococcus equi RE1
Unmarked gene deletion mutants of R. equi RE1 were
constructed essentially as described previously [34]. All oligonu-
cleotide primers used in the construction of plasmids necessary for
the construction of the mutants are shown in Table S2. Plasmid
pSelAct-ipd1, for the generation of an unmarked gene deletion of
the ipdAB operon in R. equi RE1, was constructed as follows. The
upstream (1,368 bp; primers ipdABequiUP-F and ipdABequiUP-
R) and downstream (1,396 bp; primers ipdABequiDOWN-F and
ipdABequiDOWN-R) flanking regions of the ipdAB genes were
amplified by PCR. The obtained amplicons were ligated into
EcoRV digested pBluescript(II)KS, rendering plasmids pEqui14
and pEqui16 for the upstream and downstream region, respec-
tively. A 1.4 kb SpeI/EcoRV fragment of pEqui14 was ligated into
SpeI/EcoRV digested pEqui16, generating pEqui18. A 2.9 kb
EcoRI/HindIII fragment of pEqui18, harboring the ipdAB gene
deletion and its flanking regions, was treated with Klenow
fragment and ligated into SmaI digested pSelAct suicide vector
[34]. The resulting plasmid was designated pSelAct-ipd1 for the
construction of ipdAB gene deletion mutant R. equi DipdAB.
Complementation of mutant strain RE1DipdAB was performed by
introduction of a 4.4 kb DNA fragment obtained by PCR using
primers ipdABequiContrUP-F and ipdABequiContrDOWN-R.
The PCR product obtained was cloned into pSET152 and the
resulting construct was introduced into RE1DipdAB by electropo-
ration [34].
Mutant strain RE1DipdA2B2 was constructed by unmarked
gene deletion of the ipdA2B2 operon from R. equi RE1 using
plasmid pSelAct-DipdAB2. Double gene deletion mutant R. equi
RE1DipdABDipdA2B2 was made in R. equi RE1DipdAB mutant
strain. Plasmid pSelAct-DipdAB2 was constructed as follows. The
upstream (1,444 bp; primers ipdAB2equiUP-F and ipdAB2e-
quiUP-R) and downstream (1,387 bp; ipdAB2equiDOWN-F,
ipdAB2equiDOWN-R) regions of ipdAB2 were amplified by
PCR using genomic DNA as template (Table S2). The amplicons
were ligated into SmaI digested pSelAct, resulting in plasmids
pSelAct-ipdAB2equiUP and pSelAct-ipdAB2equiDOWN, respec-
tively. Following digestion with BglII/SpeI of both plasmids, a
1,381 bp fragment of pSelAct-ipdAB2equiDOWN was ligated
into pSelAct-ipdAB2equiUP, resulting in pSelAct-DipdAB2 used
for the construction of a DipdA2B2 gene deletion.
Plasmid pSelAct-fadE30 for the generation of an unmarked
gene deletion of fadE30 in R. equi RE1 was constructed as follows.
The upstream (1,511 bp; primers fadE30equiUP-F and fadE30e-
quiUP-R) and downstream (1,449 bp; primers fadE30equi-
DOWN-F and fadE30equiDOWN-R) flanking genomic regions
of fadE30 were amplified by a standard PCR using High Fidelity
DNA polymerase (Fermentas GmbH). The obtained amplicons
were ligated into the pGEM-T cloning vector (Promega Benelux),
rendering pGEMT-fadE30UP and pGEMT-fadE30DOWN. A
1.4 kb BcuI/BglII DNA fragment was cut out of pGEMT-
fadE30DOWN and ligated into BcuI/BglII linearized pGEMT-
fadE30UP, resulting in pGEMT-fadE30. To construct pSelAct-
fadE30, pGEMT-fadE30 was digested with NcoI and BcuI and
treated with Klenow fragment. A 2.9 kb blunt-end DNA
fragment, carrying the fadE30 gene deletion, was ligated into SmaI
digested pSelAct [34]. The resulting plasmid was designated
pSelAct-fadE30 and used for the construction of mutant strain R.
equi RE1DfadE30. Complementation of mutant strain RE1D-
fadE30 was performed by the introduction of a 2.8 kb DNA
fragment obtained by PCR using primers fadE30equiUP-F and
fadE30Contr-R (Table S2). The PCR product obtained was
cloned into EcoRV digested pSET152 and the resulting construct
was introduced into RE1DfadE30 by electroporation [34].
Plasmid pSelAct-fadA6 for the generation of an unmarked gene
deletion of fadA6 in R. equi RE1 was constructed as follows. The
upstream (1,429 bp; primers fadA6equiUP-F and fadA6equiUP-
R) and downstream (1,311 bp; primers fadA6equiDOWN-F and
fadA6equiDOWN-R) flanking genomic regions of fadA6 were
amplified by a standard PCR using High Fidelity DNA
polymerase (Fermentas GmbH). The obtained amplicons were
ligated into the pGEM-T cloning vector (Promega Benelux),
rendering pGEMT-fadA6UP and pGEMT-fadA6DOWN. A
1.4 kb SpeI/BglII DNA fragment was cut out of pGEMT-fadA6UP
and ligated into SpeI/BglII linearized pGEMT-fadA6DOWN,
resulting in pGEMT-fadA6. To construct pSelAct-fadA6,
pGEMT-fadA6 was digested with EcoRI and a 2.7 kb DNA
fragment, carrying the fadA6 gene deletion, was ligated into EcoRI
digested pSelAct [34]. The resulting plasmid was designated
pSelAct-fadA6 and used for the construction of mutant strain R.
equi RE1DfadA6.
GC analysis of HIP and 5OH-HIP formation in whole-cell
biotransformations of AD
Strains were pre-grown (30uC, 200 rpm) in LB medium (10 ml)
overnight and subsequently inoculated (1:100) in 50 ml MM-Ac
and incubated (30uC, 200 rpm) for 36 hours. AD (0.5 ml of
50 mg/ml stock in DMSO) was then added. Samples (0.25 ml) for
GC analysis were collected and acidified with 5 ml 10% H2SO4 at
several intervals. Progesterone (10 ml of a 5 mg/ml stock in
ethylacetate) was added as an internal standard and samples were
subsequently extracted using ethylacetate (1 ml). GC analysis was
performed on a GC8000 TOP (Thermoquest Italia, Milan, Italy)
equipped with an EC-5 column measuring 30 m by 0.25 mm
(inner diameter) and a 0.25 mm film (Alltech, Ill., USA.) and FID
detection at 300uC. Chromatographs obtained were analysed
using Chromquest V 2.53 software (Thermoquest). HIP (200 mg/
L) and 5OH-HIP (50 mg/L), supplied by MSD Oss, The
Netherlands, were used as authentic samples.
Role Steroid Catabolism in R. equi Pathogenicity
PLoS Pathogens | www.plospathogens.org 13 August 2011 | Volume 7 | Issue 8 | e1002181
Macrophage infection assays
The human monocyte cell line U937 [66] was grown in RPMI
1640 (Invitrogen) + NaHCO3 (1 g/L) + sodium pyruvate (0.11 g/
L) + glucose medium (4.5 g/L) (RPMI 1640 medium), buffered
with 10 mM HEPES (Hopax fine chemicals, Taiwan) and
supplemented with penicillin (200 IU/ml), streptomycin
(200 IU/ml) and 10% fetal bovine serum (FBS). The cells were
grown in suspension at 37uC and 5% CO2. For the macrophage
survival assay, monocytes were grown for several days as described
above. The culture medium was replaced with fresh culture
medium and the cells were activated overnight with phorbol 12-
myristate 13-acetate (60 ng/ml, PMA, Sigma-Aldrich) to induce
their differentiation to macrophages. The differentiated cells were
spun down (5 min at 200 x g) and the pellet was re-suspended in
fresh, antibiotic free RPMI 1640 medium with 10% FBS. For each
strain to be tested, a tube containing 10 ml of a cell suspension
(approximately 106 cells/ml) was inoculated with R. equi, pre-
grown in nutrient broth (Difco, Detroit, MI., USA) at 37uC, at a
multiplicity of infection (MOI) of approximately 10 bacteria per
macrophage. The bacteria were incubated with the macrophages
for 1 h at 37uC and 5% CO2. The medium was replaced with
10 ml RPMI1640 medium supplemented with 10% FBS and
100 mg/ml gentamycin and incubated again for 1 h to kill any
extra-cellular bacteria. In assays with complemented mutant
strains of RE1DipdAB and RE1DfadE30 ampicillin (100 mg/ml)
was added in addition to gentamycin (100 mg/ml), since the
apramycin cassette conferred gentamycin resistance. The minimal
inhibitory concentration (MIC) for ampicillin was determined at
1.5–2 mg/ml ampicillin for wild type and all mutant and
complemented mutant strains using an ampicillin Etest strip (AB
Biodisk/bioMe´rieux, Solna, Sweden). The macrophages (with
internalized R. equi) were spun down (5 min at 200 x g) and the
pellet was re-suspended in 40 ml RPMI1640 medium, buffered
with 10 mM HEPES and supplemented with 10% FBS and
10 mg/ml gentamycin, plus 10 mg/ml ampicillin in assays with the
complemented mutant strains. This suspension was divided over
four culture bottles (10 ml each) and incubated at 37uC and 5%
CO2. After 4, 28, 52 and 76 h the macrophages (one culture bottle
per strain per time point) were spun down (5 min at 200 x g) and
the pellet washed twice in 1 ml antibiotic free RPMI1640
medium. Finally the pellet was lysed with 1% Triton X-100
(Sigma-Aldrich) in 0.01M phosphate buffered saline, followed by
live count determination (plate counting).
Intratracheal challenge of foals with R. equi RE1DipdAB
Six 3 to 5-week-old foals were allotted with mare to two groups
of three foals, ensuring an even distribution of age over the groups.
At T = 0 all foals were challenged with 100 ml suspension of
RE1DipdAB or R. equi RE1 (control) by trans-tracheal injection.
Bacterial suspensions of R. equi strains RE1 or RE1DipdAB were
made by plating onto blood agar (Biotrading Benelux, Mijdrecht,
The Netherlands) and incubation for 24 h at 37uC. Bacteria were
then harvested with 4 ml of sterile isotonic PBS per plate and
diluted with sterile isotonic PBS to a final concentration of
approximately 56104 CFU/ml. Live count determination by plate
counting was performed post-challenge. Infectivity titers were
determined at 4.36104 CFU/ml for RE1 and 7.16104 CFU/ml
for RE1DipdAB. Foals were examined daily post-challenge until
necropsy for clinical signs using a numerical clinical scoring system
with 13 parameters (Table S3). The clinical score was calculated as
the sum of clinical scores of the 13 different parameters. At day 21
post-challenge a post-mortem examination was performed. The
foals were euthanized by anaesthesia with xylazine (100 mg/
100 kg) and ketamine (500 mg/100 kg) and subsequent bleeding
to death. The lungs were weighed in order to calculate the lung to
body weight ratio. Details of these examinations are described
below for the immunization experiment.
Oral immunization of foals and subsequent challenge
with virulent strain R. equi 85F
Oral immunization of foals was based on a study done by
Hooper McGrevy et al. (2005) [53] with modifications. Eight 2 to
4-week-old foals were allotted to two groups of four foals each,
ensuring an even distribution of age over the groups. During the
experiment the foals suckled and the mares were fed according to
standard procedures. R. equi strain RE1DipdAB was administered
orally (1 ml) to the foals for vaccination at T = 0 and a booster at
T = 14 days. The infectivity titer of RE1DipdAB was determined by
plate counting (8.76107 CFU/ml and 4.16107 CFU/ml for the
first and second vaccination, respectively). R. equi strain 85F
(CNCM I-3250; [52,64]) was used as challenge strain and plated
onto blood agar and incubated for 24 h at 37uC. Bacteria were
harvested with 4 ml of sterile isotonic PBS per plate and diluted
with sterile isotonic PBS to a final concentration of approximately
56104 CFU/ml. At T = 28 days all foals were challenged with
100 ml R. equi 85F by trans-tracheal injection. Live count
determination by plate counting was performed post-challenge
in order to confirm the infectivity titer. Foals were examined daily
for clinical signs using the numerical clinical scoring system
described above (Table S3). Foals were weighed and blood was
sampled at day of vaccination, day of challenge and at day of
necropsy. Serum antibody titers against R. equi were determined as
follows. R. equi strain 85F cell wall extract was prepared by
resuspension of cells in 2% Triton X-114. The detergent phase
containing VapA and other surface molecules (13.5 mg protein/
ml) was diluted 2000x in 40 mM PBS and coated to microtiter
plates during 16 h at 37uC. After washing with 40 mM PBS +
0.05% Tween, serial dilutions of test sera were made in the wells.
After incubation for 1 h at 37uC and subsequent washing, the
bound antibodies were quantified using HRP-rec protein G
conjugate and 3,39,5,59-tetramethylbenzidine (TMB) as substrate.
The antibody titers in sera were calculated using a positive
standard serum with a defined titer of 9 (log2) as reference. Rectal
swabs for bacterial re-isolation were sampled just before each
vaccination and on frequent days after vaccination. The swab
samples were serially diluted in physiological salt solution and
plated on blood agar and incubated at 37uC for 16–24 h. R. equi
colonies were initially identified by the typical non-hemolytic
mucoid colony morphology, enumerated and expressed as CFU/
ml.
At day 14 (controls; T = 42 days) or day 17–20 (vaccinates;
T = 45–48 days) post-challenge foals were euthanized. The lungs
were weighed in order to calculate the lung to body weight ratio. A
complete post-mortem examination was performed with special
attention to the lungs and gut with associated lymph nodes. Tissue
samples (1 cm3) were excised from seven standard sites represen-
tative of the lobes of each half of the lung (3 sites per half and the
accessory lobe); diseased tissue was preferentially selected for each
site. The mirror image samples (the two samples of the equivalent
lobe on each half) were pooled to give three samples per foal and a
sample of the accessory lobe. Each (pooled) sample was
homogenized, serially diluted and inoculated on blood agar plates
and then incubated at 37uC for 16–24 h. R. equi colonies were
enumerated and expressed as CFU/ml homogenate.
Ethics statement
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The protocol was approved by the Committee on the Ethics of
Animal Experiments of Intervet International bv (Permit Number:
REV 07060).
Statistical analysis
The R. equi counts (log10 CFU/ml) after incubation with
macrophages for 4, 28, 52 and 76 h, reflecting the survival rate,
were statistically analysed by ANOVA using a linear mixed model
for repeated measurements and including time zero counts as
covariate in the model Verbeke and Molenberghs [67]. Advanced
statistical methods were applied for the ordinal scores over time of
the daily clinical score using Generalized Estimating Equations
(GEE with p-values based on empirical standard error) and
ANOVA for repeated measurements for continuous outcomes of
rectal temperature, lung scores (% consolidation) and the
quantitative re-isolation of R. equi from the different lung lobes.
In these methods the correlation of the repeated measurements on
subjects (i.e. animals) is taken into account. Statistical methods
were conducted in SAS V9.1 (SAS Institute Cary, NC, USA) using
two-sided tests and a significance level (a) of 0.05.
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